Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2010 14
2011 18
2012 11
2013 8
2014 1
2015 2
2016 2
2017 5
2018 3
2019 3
2020 9
2021 3
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Tanaka K, et al. Among authors: sakamori y. Sci Transl Med. 2022 Dec 14;14(675):eabq0021. doi: 10.1126/scitranslmed.abq0021. Epub 2022 Dec 14. Sci Transl Med. 2022. PMID: 36516270
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Hashimoto K, Ozasa H, Yoshizawa A, Yoshida H, Ogimoto T, Hosoya K, Yamazoe M, Ajimizu H, Funazo T, Yoshida H, Sakamori Y, Hirai T. Hashimoto K, et al. Among authors: sakamori y. Oncol Lett. 2022 Sep 22;24(5):402. doi: 10.3892/ol.2022.13522. eCollection 2022 Nov. Oncol Lett. 2022. PMID: 36276492 Free PMC article.
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T. Yamazoe M, et al. Among authors: sakamori y. Cancer Sci. 2023 Feb;114(2):546-560. doi: 10.1111/cas.15622. Epub 2022 Nov 23. Cancer Sci. 2023. PMID: 36285485 Free PMC article.
Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T. Yoshida H, et al. Among authors: sakamori y. Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745. Ann Oncol. 2018. PMID: 29161357 Free article. No abstract available.
Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T, Matsubara J, Quy PN, Fukuyama K, Nomura M, Funakoshi T, Doi K, Sakamori Y, Yoshioka M, Yokoyama A, Tamaoki M, Kou T, Hirohashi K, Yamada A, Yamamoto Y, Minamiguchi S, Nishigaki M, Yamada T, Kanai M, Matsumoto S, Muto M. Kondo T, et al. Among authors: sakamori y. Cancer Sci. 2021 Jan;112(1):296-304. doi: 10.1111/cas.14674. Epub 2020 Nov 21. Cancer Sci. 2021. PMID: 33007138 Free PMC article.
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, Kuninaga K, Ogimoto T, Hosoya K, Yamazoe M, Tsuji T, Yoshida H, Itotani R, Ueno K, Kim YH, Muro S, Hirai T. Ajimizu H, et al. Among authors: sakamori y. Sci Rep. 2023 Feb 6;13(1):2117. doi: 10.1038/s41598-023-29102-0. Sci Rep. 2023. PMID: 36747076 Free PMC article. No abstract available.
73 results